P/B
14
Arcutis Biotherapeutics
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
$3.4B
Market Cap • 11/5/2026
2016
(10 years)
Founded
2020
(6 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
6,7
P/EBITDA
91,3
P/OCF
56,9
P/FCF
57,2
P/E
128,6
BVPS
1,9
EPS
0,2
Market Cap
Market Cap
3,4B
EV
3,3B
EV/Revenue
6,4
EV/EBITDA
87,4
EV/EBIT
93
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,3%
Total Yield
-0,3%
Payout
0%
Retained Earnings
-1,1B
Profitability
Gross Margin
91,2%
EBITDA Margin
7,4%
EBIT Margin
6,9%
Net Margin
5,9%
D&A/EBITDA
0%
R&D/Revenue
18,5%
Capex/Revenue
0,1%
Capex/D&A
11,3%
Capex/OCF
0,4%
SBC/OCF
76,5%
% PPE
0,9%
% Goodwill
0%
ROE
14,9%
ROIC
37,9%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
2,9
Quick Ratio
2,5
Interest Coverage
256%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!